|
|
Volumn 13, Issue 1, 2008, Pages 15-18
|
|
Supply of new pharmaceuticals in private health insurance compared to statutory health insurance;Die verordnungen von neuen arzneimitteln bei privatversicherten im vergleich zu GKV-versicherten
|
|
Author keywords
Innovation; Pharmaceuticals; Private health insurance; Statutory health insurance; System comparison
|
|
Indexed keywords
ADALIMUMAB;
ATAZANAVIR;
ATORVASTATIN;
AVOLAX;
BETA1A INTERFERON;
CABERGOLINE;
CANDESARTAN HEXETIL;
CLOPIDOGREL;
EFAVIRENZ;
ESCITALOPRAM;
ESOMEPRAZOLE;
ETANERCEPT;
ETORICOXIB;
EZETIMIBE;
FENTANYL;
GLATIRAMER;
GONAL;
IMATINIB;
INFLIXIMAB;
INSULIN GLARGINE;
INTERFERON BETA SERINE;
LEVOFLOXACIN;
LOSARTAN;
LOSARTAN POTASSIUM;
MONTELUKAST;
MOXIFLOXACIN;
NEXIUM MUPS;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PEGINTERFERON ALPHA2A;
PREGABALIN;
RECOMBINANT FOLLITROPIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
TIOTROPIUM BROMIDE;
UNCLASSIFIED DRUG;
VENLAFAXINE;
ARTICLE;
CONTRACT;
HEALTH INSURANCE;
PRIVATE HEALTH INSURANCE;
TREATMENT INDICATION;
|
|
EID: 40149095142
PISSN: 14322625
EISSN: None
Source Type: Journal
DOI: 10.1055/s-2007-963329 Document Type: Article |
|
Times cited : (3)
|
|
References (8)
|
